UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038594
Receipt number R000042983
Scientific Title A prospective observational study of pembrolizumab and chemotherapy for lung cancer patients with interstitial abnormalities
Date of disclosure of the study information 2019/11/21
Last modified on 2022/06/13 08:00:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A prospective observational study of pembrolizumab and chemotherapy for lung cancer patients with interstitial abnormalities

Acronym

Pembrolizumab and chemotherapy for lung cancer patients with interstitial abnormalities

Scientific Title

A prospective observational study of pembrolizumab and chemotherapy for lung cancer patients with interstitial abnormalities

Scientific Title:Acronym

Pembrolizumab and chemotherapy for lung cancer patients with interstitial abnormalities

Region

Japan


Condition

Condition

non-small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate for probability of pneumonitis in advanced non-small cell lung cancer patients with interstitial lung abnormalities treated with pembrolizumab plus platinum-based chemotherapy.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The probability of pneumonitis in treatment of pembrolizumab plus platinum-based chemotherapy

Key secondary outcomes

1) Objective response rate
2) Disease control rate
3) Relapse free survival
4) Severity of pneumonitis
5) Provability of pneumonitis during observation period
6) Time to occurrence of pneumonitis
7) Probability of occurrence of adverse events


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Patients aged over 20 years old
2)Advanced or postoperative recurrence non-small cell lung cancer
3)Pembrolizumab plus platinum combination chemotherapy is planned as clinical practice.
4)The proportion of linear shadows, reticular abnormalities, or ground-glass abnormalities are less than 10% of all lung fields.
5) Written informed consent is obtained.

Key exclusion criteria

1)Patients with history of drug induced pneumonitis.
2)Patients who has increased infiltration other than lung cancer within 1 month.
3)Patients with interstitial pneumonitis with UIP pattern on computed tomography.
4)Patients with interstitial pneumonitis associated with collagen diseases.
5)Pregnant women and patients who may be pregnant or breastfeeding.
6)Patients who are judged to be inappropriate for the study by the investigator.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Motoko
Middle name
Last name Tachihara

Organization

Kobe University Graduate School of Medicine

Division name

Division of Respiratory Medicine, Department of Internal Medicine

Zip code

650-0017

Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan

TEL

81-78-382-5661

Email

mt0318@med.kobe-u.ac.jp


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Katsurada

Organization

Kobe University Graduate School of Medicine

Division name

Division of Respiratory Medicine, Department of Internal Medicine

Zip code

650-0017

Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan

TEL

81-78-382-5661

Homepage URL


Email

nk1208@med.kobe-u.ac.jp


Sponsor or person

Institute

Kobe University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Kobe University Graduate School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board, Kobe University Hospital Clinical Translational Research Center

Address

7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Japan

Tel

078-382-6669

Email

kansatsu@med.kobe-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 11 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

2

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2019 Year 11 Month 15 Day

Date of IRB

2019 Year 11 Month 20 Day

Anticipated trial start date

2019 Year 11 Month 21 Day

Last follow-up date

2021 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2019 Year 11 Month 15 Day

Last modified on

2022 Year 06 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042983


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name